Select Clinical Trial
Protocol Number: AGENUS C750-01/GOG 3028 Cervical
Protocol Title: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line).
Eligibility: Patient population 18 years and older with confirmed cervical cancer that has already been treated with other therapies and your cancer has recurred or is not responding to those treatments.
Contact Information: (910) 715-2200